Prof. Jiahai Shi
Prof. Jiahai Shi is the scientific co-founder of Carcell Biopharma. Dr. Shi has 20 years’ experience in the development of bio-therapeutics . He participated in the vaccine development against hepatitis E virus (HEV), which was commercialized under the trade name Hecolin (益可宁) in 2012. During his PhD studies, Dr. Shi developed novel strategies for drug development against Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), by targeting its main protease (SARS-CoV Mpro). During his post-doc training with Professor Harvey Lodish, Dr. Shi co-invented a new technology for engineering red blood cells as carriers for a wide range of therapeutic cargoes, particularly for therapeutic proteins. This invention led to the establishment of Rubius Therapeutics, which went public in 2018 and reached a market capitalization of almost 2 billion USD.
After setting up his own lab, Dr. Shi is focused on the development of novel therapeutics, including gene therapy, genome editing and antibody drugs. Working with his collaborators, Dr. Shi engineers red blood cell extracellular vesicles (RBCEV) as a non-viral gene delivery vehicle. Again, this innovation has led to the establishment of Carmine Therapeutics, co-founded with Harvey Lodish, Minh Le and EVX Ventures.
Dr. Shi received his Bachelor’s Degree in Biological Sciences from Xiamen University and his Ph.D. from National University of Singapore. He was a post-doc fellow at MIT Whitehead Institute, and he is presently an Associate Professor at the National University of Singapore.